Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Mclean Hospital
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00762268CT.gov A Trial of SAMe for Treatment-Resistant Bipolar Depression | — | Completed | — | — | — |
NCT00101452CT.gov Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression | — | Completed | — | — | — |
NCT00093847CT.gov Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression | — | Completed | — | — | — |
NCT00070941CT.gov SAM-e for the Treatment of Depression in Patients With Parkinson's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| S,S-Adenosylmethionine (this asset) | Mclean Hospital | P2/3 | B · 63 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for S,S-Adenosylmethionine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis | — | P3 | B · 62 |
| Cirrhosis Of Liver | — | P2 | CCC · 53 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. S,S-Adenosylmethionine in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ss-adenosylmethionine-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →